POINT Biopharma Announces Appointment of Dr. Bridget Martell to its Board of Directors
12 Juni 2023 - 2:00PM
POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or
“POINT”), a company accelerating the discovery, development, and
global access to life-changing radiopharmaceuticals, today
announced the filling of its vacant board seat with the appointment
of Bridget Martell, M.A., M.D. to its Board of Directors.
"On behalf of POINT and the Board of Directors,
I am pleased to welcome Dr. Martell, an experienced biotech board
executive who brings extensive drug development, operational, and
commercial expertise in both oncology and precision medicine," said
Allan Silber, Executive Chairman of POINT Biopharma. "Her
experience and perspectives will be a complement to our board,
helping to lead our company as we continue to advance our pipeline
of next-generation radioligands.”
Dr. Martell is a seasoned pharmaceutical
executive with a demonstrated track record in both drug development
and financing, building, and leading highly successful biotech
companies. She started her pharmaceutical career at Pfizer, where
she had roles of increasing responsibility in both the oncology and
biosimilars business units. Dr. Martell has held leadership and
C-suite executive roles at companies including Kura Oncology and
Juniper Pharmaceuticals, and has been a pivotal leader or major
contributor in the success of six marketed products: Kadcyla®,
Elelyso®, Intermezzo®, the trastuzumab biosimilar Ogiviri®, as well
as secondary indications for Pradaxa® and Sutent®. Dr. Martell is
currently President and Chief Executive Officer of Artizan
Biosciences, Inc., a precision medicine drug development platform
company focusing on inflammatory disease and the microbiome. She
holds a B.Sc. in Microbiology from Cornell University, an M.A. in
Molecular Immunology from Boston University, and an M.D. from the
Chicago Medical School.
About POINT Biopharma Global
Inc.
POINT Biopharma Global Inc. is a globally
focused radiopharmaceutical company building a platform for the
clinical development and commercialization of radioligands that
fight cancer. POINT aims to transform precision medicine by
combining a portfolio of targeted radioligand assets, a seasoned
management team, an industry-leading pipeline, in-house
manufacturing capabilities, and secured supply for medical isotopes
including actinium-225 and lutetium-177. POINT’s active clinical
trials include FRONTIER, a phase 1 trial for PNT2004, a pan-cancer
program targeting fibroblast activation protein-α (FAP-α), and
SPLASH, the phase 3 trial for PNT2002 for people with metastatic
castration resistant prostate cancer (mCRPC) after second-line
hormonal treatment. Learn more about POINT Biopharma Global Inc.
at https://www.pointbiopharma.com/.
Forward Looking Statements
This press release contains forward-looking
statements within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995. In some
cases, you can identify forward-looking statements by the following
words: “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. Although we believe that we
have a reasonable basis for each forward-looking statement
contained in this press release, we caution you that these
statements are based on a combination of facts and factors
currently known by us and our projections of the future, about
which we cannot be certain. Forward-looking statements in this
press release include, but are not limited to, statements regarding
the potential attributes and benefits of POINT’s product candidates
and the format and timing of POINT’s product development activities
and clinical trials. We cannot assure you that the forward-looking
statements in this press release will prove to be accurate. These
forward-looking statements are subject to a number of significant
risks and uncertainties that could cause actual results to differ
materially from expected results, including, among others, our
ability to obtain funding for our operations, our ability to
maintain the license agreements underlying our product candidates,
competition, the ability of POINT to grow and manage growth
profitably and retain its key employees, the impact of COVID-19 on
POINT’s business, the ability to maintain the listing of POINT’s
common stock on the NASDAQ, changes in applicable laws or
regulations, the possibility that POINT may be adversely affected
by other economic, business, and/or competitive factors, and other
risks and uncertainties, including those described in POINT's
Annual Report on Form 10-K filed with the SEC on March 27, 2023 and
subsequent filings with the SEC. Most of these factors are outside
of POINT’s control and are difficult to predict. Furthermore, if
the forward-looking statements prove to be inaccurate, the
inaccuracy may be material. In light of the significant
uncertainties in these forward-looking statements, you should not
regard these statements as a representation or warranty by us or
any other person that we will achieve our objectives and plans in
any specified time frame, or at all. The forward-looking statements
in this press release represent our views as of the date of this
press release. We anticipate that subsequent events and
developments will cause our views to change. However, while we may
elect to update these forward-looking statements at some point in
the future, we have no current intention of doing so except to the
extent required by applicable law. You should, therefore, not rely
on these forward-looking statements as representing our views as of
any date subsequent to the date of this press release.
Investor Relations
Contact:Daniel PearlsteinDirector,
Strategyinvestors@pointbiopharma.com
POINT Biopharma Global (NASDAQ:PNT)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
POINT Biopharma Global (NASDAQ:PNT)
Historical Stock Chart
Von Mai 2023 bis Mai 2024